Generic Name: cemiplimab-rwlc

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Immunotherapy Medications

Company: Regeneron/ Sanofi

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Libtayo is a checkpoint inhibitor approved for two types of skin cancer, metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) and advanced basal cell carcinoma, and for advanced or metastatic non-small-cell lung cancer with high PD-L1 expression.

General Info

Libtayo is a monoclonal antibody used in cancer immunotherapy. It is a checkpoint inhibitor that blocks the PD-1 receptor on T cells. PD-1 plays a role in regulating immune function. Some tumors can hijack PD-1 to turn off immune responses against them. Drugs that block the interaction between PD-1 and its binding partner, known as PD-L1, can release the brakes and restore T-cell activity against cancer.

Clinical trials showed that Libtayo led to complete or partial tumor shrinkage in a quarter to a half of skin cancer patients. Responses were generally durable for at least six months. and 37% of lung cancer patients. For those with non-small-cell lung cancer, the overall response rate was 37%, and progression-free and overall survival improved compared with chemotherapy.


Dosing Info:

Libtayo is administered as an intravenous infusion once every three weeks until disease progression or unacceptable side effects occur.

Side Effects

Common side effects include fatigue, skin rash and diarrhea. Checkpoint inhibitors can cause an overactive immune response that harms healthy organs and tissues. Serious immune-mediated side effects can affect almost any organ including the lungs, heart, liver, intestines, skin and hormone-producing endocrine glands.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: February 24, 2021